Health insurance companies are lobbying the Trump administration to reject Biden-era proposals that would expand Medicare and ...
Artificial intelligence tools continue to be a focal point among publicly traded digital health companies looking to improve ...
New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...
As original Medicare faces funding shortfalls, Dr. Oz may shift to private insurance providers through Medicare Advantage.
Zepbound may not be as widely known as its competitors, but the weight-loss drug may soon be more accessible than the rest.
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Medicare, the government-backed program for adults aged 65 and older and those with disabilities, only covers the use of ...
Coverage complications are not unusual in the U.S. healthcare system. But the challenge is magnified for these obesity ...
Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent ...
Medicare Part D spending for 10 selected diabetes drugs totaled more than $35.8 billion in 2023, a 364% increase from 2019, according to a new data brief from the Department of Health and Human Servic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback